New first-in-human study explores immune-engineered cell therapy approach for type 1 diabetes

New probe presented astatine the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting explores an attack that could grow the imaginable of compartment replacement therapy for benignant 1 diabetes by evaluating whether immune-engineered, allogeneic insulin-producing cells tin past and relation without chronic immunosuppression.